New bladder cancer cocktail aims to spare patients from surgery
NCT ID NCT06829823
First seen Nov 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This phase 2 trial tests whether a drug called N-803, combined with either BCG or gemcitabine, can treat intermediate-risk bladder cancer without needing surgery. About 20 adults with low-grade papillary tumors will receive the drugs directly into the bladder. The main goal is to see if the cancer disappears by 3 or 6 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
N-803 (a drug that boosts the immune system) combined with either BCG (a weakened bacteria used in immunotherapy) or gemcitabine (a chemotherapy drug)
What this could lead to
If successful, this could offer a way to treat intermediate-risk bladder cancer without surgery, using a combination of immune-boosting and standard therapies.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply to everyone. The treatments may cause side effects or fail to control the cancer long-term.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.